MOMaksim Ovcharov

Maksim Ovcharov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maksim Ovcharov has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Features of calcium-phosphorus metabolism and vitamin D metabolism in patients with chronic kidney disease at predialysis stages during bolus cholecalciferol therapy

    by A. S. Bondarenko, L. Ya. Rozhinskaya, A. Yu. Zhukov, V. A. Ioutsi, M. V. Ovcharov, G. S. Kolesnikova, A. I. Sleptsova, N. P. Trubitsyna, V. E. Vinogradov, O. N. Kotenko, et al.

    Background . Chronic kidney disease (CKD) is associated with disturbances in calcium-phosphate homeostasis and vitamin D metabolism, leading in mineral and bone disorders (CKD-MBD). However, the pathogenetic features of these alterations at predialysis CKD stages and the effects of high-dose cholecalciferol therapy remain insufficiently characterized. Objective . To compare vitamin D metabolites and calcium-phosphate metabolism parameters in patients with predialysis CKD and individuals without impaired kidney function, and to assess their dynamics after a single bolus dose of 150,000 IU of cholecalciferol. Materials and Methods . The study included 58 participants: 23 patients with CKD stage C3, 14 with CKD stages C4-5, and 21 controls. Parameters of calcium-phosphate metabolism and vitamin D metabolites were assessed at baseline and 7 days after a single oral dose of aqueous cholecalciferol (150,000 IU). Vitamin D metabolites were measured using LC–MS/MS. Results . Data are presented as follows: control group, CKD C3, CKD C4-5. At baseline, CKD patients had higher parathyroid hormone (PTH) levels (51.3 [40.6; 62.7] vs 70.9 [49.0; 105.9] vs 101.0 [91.7; 120.1] pg/mL), lower calcitriol concentrations (40.9 [34.3; 59.4] vs 25.0 [19.8; 29.1] vs 26.4 [13.8; 30.6] pg/mL), a trend toward higher fibroblast growth factor 23 (FGF-23) levels (0.73 [0.43; 1.07] vs 1.08 [0.61; 2.52] vs 3.22 [1.78; 4.51] pmol/L), and a reduced 24,25 (OH) 2 D 3 /25(OH)D 3 ratio (0.06 [0.04; 0.08] vs 0.03 [0.01; 0.04] vs 0.03 [0.02; 0.04]), indicating impaired 24-hydroxylase activity. Total and free 25(OH)D levels and vitamin D-binding protein (VDBP) were comparable between groups. Seven days after cholecalciferol administration, a similar increase in total 25(OH)D 3 , 3-epi-25(OH)D 3 , and 24,25(OH) 2 D 3 was observed in all groups. However, the increase in free 25(OH)D was significantly smaller in CKD C3 and C4-5 compared with controls ( p =0.036 and p =0.028). PTH decreased in CKD C3 ( p =0.039), whereas FGF-23 increased in CKD C4-5 ( p =0.042). Serum calcium, phosphorus, calcitriol, and VDBP remained unchanged. Conclusion . Alterations in calcium-phosphate and vitamin D metabolism at predialysis CKD stages show a sequential pattern. Reduced vitamin D activation and inactivation, increased FGF-23 levels, and a blunted free 25(OH)D response to bolus cholecalciferol indicate specific regulatory features and limit the applicability of standard vitamin D correction regimens in this population.

  • Open Access

    Diagnostic value of the blood steroid profile in secondary amenorrhea

    by Y. S. Absatarova, E. N. Andreeva, V. A. Ioutsi, M. A. Antsupova, M. V. Ovcharov, Y. S. Evseeva, E. V. Sheremetyeva, O. R. Grigoryan, Z. A. Uzhegova

    BACKGROUND. Secondary amenorrhea is a pathological condition that may develop as a result of either functional hypothalamic amenorrhea (FHA) or primary ovarian insufficiency (POI). In recent years, metabolomic studies in gynecology have gained importance for improving diagnostics, optimizing pharmacological treatment, and monitoring therapeutic outcomes. It is well established that cortisol production increases in response to chronic stress and relative energy deficiency syndrome. Therefore, it is reasonable to expect elevated cortisol levels in patients with functional amenorrhea associated with weight loss, which may adversely affect menstrual function. OBJECTIVE. To investigate and compare the parameters of the multicomponent blood steroid profile (multisteroid analysis), including androstenedione, corticosterone, testosterone, cortisol, cortisone, and dehydroepiandrosterone (DHEA), in patients with secondary amenorrhea of different origins (FHA, POI), and to identify alterations in target markers using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). MATERIALS AND METHODS. A single-center cross-sectional comparative study was conducted involving two populations of women aged 18–39 years: (1) patients with secondary amenorrhea of various origins (FHA, POI) (n=120), and (2) healthy women (n=34). Blood steroid profile parameters were assessed using HPLC-MS/MS. RESULTS. A total of 154 women were examined. The lowest corticosterone levels were observed in the POI group — 3.95 nmol/L [2.4; 5.7] (pCONCLUSION. In this study, based on a targeted quantitative analysis of steroid hormones, their precursors, and metabolites using HPLC-MS/MS technology, we characterized the features of the blood steroid profile in patients with secondary amenorrhea. The profile demonstrated similar characteristics across all amenorrhea types, regardless of etiology, suggesting a common underlying mechanism. However, the observed decrease in corticosterone levels in POI patients and the absence of hypercortisolemia in FHA women are of particular interest and warrant further investigation.


  • Differential diagnosis of hyperandrogenism

    by Ivashchenko K.V. Ivashchenko, Molashenko N.V. Molashenko, Platonova N.M. Platonova, Roslyakova A.A. Roslyakova A, Ioutsi V.A. Ioutsi, Ovcharov M.V. Ovcharov, Antsupova M.A. Antsupova M, Lapshina A.M. Lapshina, Buryakina S.A. Buryakina, Beltsevich D.G. Beltsevich D, et al.

  • Open Access

    Dynamic Evaluation of Vitamin D Metabolism in Post-Bariatric Patients

    by Alexandra Povaliaeva, Artem Zhukov, Alina Tomilova, Axenia Bondarenko, Maksim Ovcharov, Mariya Antsupova, Vitaliy Ioutsi, Ekaterina Shestakova, Marina Shestakova, Ekaterina Pigarova, et al.

    Background: findings from the previously conducted studies indicate altered regulatory mechanisms of calcium and vitamin D metabolism in obese patients and a role for bariatric surgery in regulating vitamin D metabolism; however, the available data is controversial and does not provide an adequate understanding of the subject. Methods: we evaluated serum parameters of vitamin D and mineral metabolism (vitamin D metabolites (25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3-epi-25(OH)D3, and 24,25(OH)2D3), vitamin D-binding protein (DBP), free 25(OH)D, fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), total calcium, albumin, phosphorus, creatinine, magnesium) in 30 patients referred for bariatric surgery in comparison with 30 healthy volunteers of similar age, sex and baseline 25(OH)D3. Patients were also followed up with repeated laboratory assessments 3 months and 6 months after surgery. During the first 3 months, patients were prescribed high-dose cholecalciferol therapy (50,000 IU per week), with subsequent correction based on the results of the 3-month visit examination. Results: Preoperatively, patients with morbid obesity were characterized by a high prevalence of vitamin D deficiency (median 25(OH)D3 level 11.9 (6.8; 22.2) ng/mL), significantly lower levels of active vitamin D metabolite 1,25(OH)2D3 (20 (10; 37) vs. 39 (33; 50) pg/mL, p < 0.001), lower serum albumin-adjusted calcium levels (2.24 (2.20; 2.32) vs. 2.31 (2.25; 2.35) mmol/L, p = 0.009) and magnesium levels (0.79 (0.72; 0.82) vs. 0.82 (0.78; 0.85) mmol/L, p = 0.043) with simultaneous similar PTH levels (p = 0.912), and higher DBP levels (328 (288; 401) vs. 248 (217; 284) mg/L, p < 0.001). The 25(OH)D3 levels remained suboptimal (24.5 (14.7; 29.5) ng/mL at the 3-month visit and 17.9 (12.4; 21.0) ng/mL at the 6-month visit, p = 0.052) despite recommended high-dose cholecalciferol supplementation. Patients also demonstrated an increase in 1,25(OH)2D3 levels (38 (31; 52) pg/mL at the 3-month visit and 49 (29; 59) pg/mL at the 6-month visit, p < 0.001) without a change in PTH or calcium levels during the follow-up. Conclusion: our results of a comprehensive laboratory evaluation of vitamin D status and mineral metabolism in patients undergoing bariatric surgery highlight the importance of improving current clinical guidelines, as well as careful monitoring and education of patients.